MedTrace Logo

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

NCT02871479 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2019-05-29

Study results available
· View outcomes & findings →

Summary

This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28 days to patients at least 18 years of age, with atopic dermatitis.

Conditions

Interventions

DRUG

SAN007 5% cream

5% EISO in a cream formulation applied twice a day for up to 28 days.

DRUG

Placebo

A placebo cream containing the same components as the vehicle for the active intervention arm

DRUG

SAN007 10% cream

10% EISO in a cream formulation applied twice a day for up to 28 days.

Sponsors & Collaborators

  • ClinDatrix, Inc.

    collaborator INDUSTRY

  • Texas Dermatology and Laser Specialists

    collaborator UNKNOWN

  • Clinical Trials of Texas, Inc.

    collaborator OTHER

  • Derm Research, PLLC

    collaborator OTHER

  • Progressive Clinical Research

    collaborator OTHER

  • U.S. Dermatology Partners Bryan

    collaborator UNKNOWN

  • Santalis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • John Browning, MD · Texas Dermatology and Laser Specialists

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-21
Primary Completion
2018-08-31
Completion
2018-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02871479 on ClinicalTrials.gov